الصفحة الرئيسية>>Signaling Pathways>> PROTAC>> E3 Ligase Ligand-Linker Conjugate>>E3 ligase Ligand-Linker Conjugates 12

E3 ligase Ligand-Linker Conjugates 12 (Synonyms: VH032-PEG3-N3; VHL Ligand-Linker Conjugates 8; E3 ligase Ligand-Linker Conjugates 12)

رقم الكتالوجGC33000

E3 ligase Ligand-Linker Conjugates 12 عبارة عن اتحاد مركب E3 ligase ligand-linker مُصنَّع يشتمل على (S ، R ، S) - AHPC على أساس VHL ورابط PEG ثلاثي الوحدات المستخدم في تقنية PROTAC.

Products are for research use only. Not for human use. We do not sell to patients.

E3 ligase Ligand-Linker Conjugates 12 التركيب الكيميائي

Cas No.: 1797406-80-4

الحجم السعر المخزون الكميّة
100mg
279٫00
متوفر
500mg
1080٫00
متوفر
1g
1993٫00
متوفر
2g
2790٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

E3 ligase Ligand-Linker Conjugates 12 is a synthesized compound that incorporates an E3 ligase ligand and a linker used in PROTAC technology.

E3 ligase Ligand-Linker Conjugates 12 is extracted from patent WO/2016/146985A1, figure 11. PROTAC has been developed having structure A-L-B that can tether a bromodomain inhibitor via a moiety which binds to a protein within the bromo- and Extra-terminal (BET) family of proteins to a small molecule E3 ubiquintin ligase protein binding ligand compond via a suitable linker[1][2].

[1]. WO/2016/146985A1 [2]. Zengerle M, et al. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4. ACS Chem Biol. 2015 Aug 21;10(8):1770-7.

مراجعات

Review for E3 ligase Ligand-Linker Conjugates 12

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for E3 ligase Ligand-Linker Conjugates 12

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.